Generics for Betmiga, ↑19% market share in just one year

The prescription amount of Mirabek & Selebeta per second quarter is ￦3.2 billion

The original's slales, ￦14 billion decreased by 14% in a year

Betmiga, Mirabek & Selebeta

Generics for Betmiga (Mirabegron) are gaining market influence.

 

Two generics for market share expanded to 19% in just one year after its launch.

 

The release of generics resulted in a 14% drop in the amount of outpatient prescriptions for the original over a year.

 

According to UBIST, a pharmaceutical market research institute on the 21st, the size of outpatient prescription market for irritable bladder treatments with Mirabegron ingredients in the second quarter was ￦17.3 billion.

 

Compared to ￦16.5 billion in the same period last year, it increased by 5 %.

 

The second-quarter prescription for the original Betmiga is ￦14 billion, down 14% from a year earlier.

 

Hanmi and Chong Kun Dang released Mirabegron and Sellebeta in June and July last year, respectively.

 

The amount of the original product decreased from ￦16.4 billion in the second quarter of last year to ￦16.1 billion in the third quarter, ￦15.9 billion in the fourth quarter, ￦15.4 billion in the first quarter and ￦14 billion in the second quarter.

 

The market share fell from 99% to 81%.

 

Considering that Betmiga's prices are almost the same as before, it is interpreted that the generics directly affected the original performance decline.

 

Astellas has postponed the decision to lower the price of generics due to administrative litigation.

 

However, since March of this year, the upper limit of insurance has been reduced by 5.5% in accordance with the price-volume agreement negotiation system.

 

The total amount of prescription for two generics in the second quarter is ￦3.2 billion.

 

Its share in the overall market is 19%.

 

It succeeded in taking up one fifth of the market within a year of its release.

 

Hanmi is ahead in the competition between the two generics.

 

As of second quarter, Mirabek recorded ￦2.4 billion and Selebeta recorded ￦800 million.

 

In particular, Mirabek is expected to achieve ￦10 billion per year.

 

The key is the additional release of generics.

 

Generic exclusivity period for Mirabek and Selebeta ended in February this year.

 

Currently, 26 companies, excluding Hanmi and Chong Kun Dang, are preparing to launch with generic approval.

 

Betmiga is an irritant bladder drug released by Astellas in October 2015.

 

Annual prescriptions include ￦28.8 billion in 2016, ￦41.9 billion in 2017, ￦54.8 billion in 2018, ￦64.7 billion in 2019, and ￦65.1 billion in 2020.

 

There are about 40 domestic companies that have entered into patent challenges.

 

Since 2015, the company has filed defensive confirmation trial for the scope of a right.

 

Among them, Hanmi and Chong Kun Dang won the generic exclusivity.

 

The generic exclusivity period was from May 4 last year to February 3 this year.